Medipal Holdings Corporation is the company’s largest shareholder holding 23.1% of shares. Explains the independence of parent-subsidiary relationships and transaction conditions. Currently no transactions with related parties. Discloses transactions with consolidated subsidiary Medisecao, including pharmaceutical procurement and accounts payable.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3034","jir_company_name":"Qol Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-06-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/3034-20260629-01.pdf","jir_short_summary":"Medipal Holdings Corporation is the company's largest shareholder holding 23.1% of shares. Explains the independence of parent-subsidiary relationships and transaction conditions. Currently no transactions with related parties. Discloses transactions with consolidated subsidiary Medisecao, including pharmaceutical procurement and accounts payable.","jir_summary":"### Relationship with Controlling Shareholders and Transactions\nThe disclosed matter confirms that Medipal Holdings Corporation, the largest shareholder, owns 23.1% of our shares directly and indirectly. The relationship explains the cooperative ties and independence between the two groups. There are no business constraints from the parent group, and the company operates independently.\n\n### Status of Transactions with Related Parties\nIt is explicitly stated that there are no applicable transactions with related parties. However, transactions with the consolidated subsidiary Medisecao include accounts payable for pharmaceutical procurement, with transaction amounts totaling 45,946 million yen and an end-of-term balance of 10,540 million yen. The transaction conditions are on par with those of ordinary business partners.","jir_financial_highlights":"Voting Rights Ownership Ratio: 23.1% (None)\nShareholder Composition & Relationships: Medipal Holdings Corporation is the largest shareholder (None)\nTransactions with Related Parties: No applicable transaction details (None)\nTransaction Amount (with Medisecao): 45,946 million yen (Unclear compared to previous period)","jir_category":"","jir_hashtags":"#QolHoldings, #IR, #JapanStocks","jir_key_figures":"Voting Rights Ownership Ratio: 23.1%\nTransaction Amount with Related Parties: 45,946 million yen\nAccounts Payable at End of Period: 10,540 million yen","jir_meta_title":"\u3010Qol Holdings\u3011Disclosure Regarding Controlling Shareholders\uff5cJune 2026","jir_meta_description":"Summary of the relationship between Qol Holdings and its largest shareholder Medipal Holdings, voting rights ratio, and an overview of related-party transactions. No applicable transactions at present.","jir_og_title":"\u3010Qol Holdings\u3011Disclosure Regarding Controlling Shareholders\uff5cJune 2026","jir_og_description":"The largest shareholder is Medipal HD with 23.1% voting rights; no current transactions with related parties. Transactions with Medisecao include accounts payable of 45,946 million yen, with an ending balance of 10,540 million yen.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16824,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-72365","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n